Compare CRMT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | CALC |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 7.6M |
| IPO Year | 2026 | 2020 |
| Metric | CRMT | CALC |
|---|---|---|
| Price | $0.94 | $1.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.50 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 401.0K | 56.2K |
| Earning Date | 12-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,281,502,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $0.44 |
| 52 Week High | $28.70 | $72.00 |
| Indicator | CRMT | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 30.40 |
| Support Level | $0.95 | $0.44 |
| Resistance Level | $1.49 | $2.31 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 45.56 | 20.80 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.